[Evaluation of Neutropenia and Usages of Antihypertensive Drugs in Patients Treated with Ramucirumab plus Paclitaxel Therapy].
Gan To Kagaku Ryoho
; 49(8): 873-878, 2022 Aug.
Article
in Ja
| MEDLINE
| ID: mdl-36046973
ABSTRACT
Hypertension is one of the main side effects of ramucirumab(RAM)plus paclitaxel(PTX)therapy. Although dihydropyridine calcium channel blockers(D-CCBs)are considered to cause drug-drug interactions with PTX based on the inhibition of cytochrome P450, D-CCBs are often administered to patients receiving RAM plus PTX therapy in clinical practice. We retrospectively studied the actual usage of antihypertensive drugs in 133 advanced or recurrent gastric cancer patients who received RAM plus PTX therapy. Antihypertensive drugs were administered to 34(25.6%)patients. Among them, 13 (38.2%)received antihypertensive drugs during the first course, and 19(55.9%)received D-CCBs. We also investigated whether D-CCBs affect the expression of Grade 3 or higher neutropenia caused by PTX. Results of multivariate analysis indicated that D-CCBs did not increase the risk of neutropenia caused by PTX.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Stomach Neoplasms
/
Neutropenia
Type of study:
Etiology_studies
/
Observational_studies
Limits:
Humans
Language:
Ja
Journal:
Gan To Kagaku Ryoho
Year:
2022
Document type:
Article